Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Alpine Immune Sciences, Inc is a biotechnology business based in the US. Alpine Immune Sciences shares (ALPN) are listed on the NASDAQ and all prices are listed in US Dollars. Alpine Immune Sciences employs 53 staff and has a trailing 12-month revenue of around USD$4.6 million.
|Latest market close||USD$10.55|
|52-week range||USD$2.05 - USD$16.37|
|50-day moving average||USD$10.5729|
|200-day moving average||USD$9.1475|
|Wall St. target price||USD$21.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.971|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-21.50%|
|1 month (2020-12-16)||-23.38%|
|3 months (2020-10-15)||20.43%|
|6 months (2020-07-15)||12.35%|
|1 year (2020-01-15)||154.22%|
|2 years (2019-01-15)||77.91%|
|3 years (2018-01-12)||11.01|
|5 years (2016-01-15)||83.48%|
|Revenue TTM||USD$4.6 million|
|Gross profit TTM||USD$-34,107,000|
|Return on assets TTM||-16.74%|
|Return on equity TTM||-54.23%|
|Market capitalisation||USD$378.5 million|
TTM: trailing 12 months
There are currently 28,151 Alpine Immune Sciences shares held short by investors – that's known as Alpine Immune Sciences's "short interest". This figure is 4.6% up from 26,922 last month.
There are a few different ways that this level of interest in shorting Alpine Immune Sciences shares can be evaluated.
Alpine Immune Sciences's "short interest ratio" (SIR) is the quantity of Alpine Immune Sciences shares currently shorted divided by the average quantity of Alpine Immune Sciences shares traded daily (recently around 97072.413793103). Alpine Immune Sciences's SIR currently stands at 0.29. In other words for every 100,000 Alpine Immune Sciences shares traded daily on the market, roughly 290 shares are currently held short.
However Alpine Immune Sciences's short interest can also be evaluated against the total number of Alpine Immune Sciences shares, or, against the total number of tradable Alpine Immune Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alpine Immune Sciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Alpine Immune Sciences shares in existence, roughly 0 shares are currently held short) or 0.0027% of the tradable shares (for every 100,000 tradable Alpine Immune Sciences shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alpine Immune Sciences.
Find out more about how you can short Alpine Immune Sciences stock.
We're not expecting Alpine Immune Sciences to pay a dividend over the next 12 months.
Alpine Immune Sciences's shares were split on a 1:4 basis on 25 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alpine Immune Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Alpine Immune Sciences shares which in turn could have impacted Alpine Immune Sciences's share price.
Over the last 12 months, Alpine Immune Sciences's shares have ranged in value from as little as $2.05 up to $16.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alpine Immune Sciences's is 1.7065. This would suggest that Alpine Immune Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.